Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 6/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22803217 | 0.90 | — | — | |
| SCHEMBL22695463 | 0.82 | ALPL (0.32) | ALPL | |
| SCHEMBL22803490 | 0.78 | — | — | |
| SCHEMBL25591664 | 0.75 | MAP4K1 (0.31) | — | |
| SCHEMBL25590844 | 0.74 | MAP4K1 (0.31) | — | |
| SCHEMBL25590843 | 0.74 | — | — | |
| SCHEMBL22803430 | 0.72 | NR3C2 (0.36) | — | |
| SCHEMBL25590840 | 0.72 | — | — | |
| SCHEMBL22695461 | 0.72 | — | — | |
| SCHEMBL22803125 | 0.72 | MAP4K1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037342-B2 | Substituted eneoxindoles and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037342-B2 | Substituted eneoxindoles and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20230183262-A1 | SUBSTITUTED ENEOXINDOLES AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-06-15 | — | — | US | disclosed |
| US-20230183262-A1 | SUBSTITUTED ENEOXINDOLES AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-06-15 | — | — | US | disclosed |
| US-20200392153-A1 | SUBSTITUTED ENEOXINDOLES AND USES THEREOF | GILEAD SCIENCES, INC. | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183262-A1 | SUBSTITUTED ENEOXINDOLES AND USES THEREOF | HIPK1, HPGDS, HIPK3 | ALPL 2514/4885 |
| US-12037342-B2 | Substituted eneoxindoles and uses thereof | HIPK1, HPGDS, HIPK3 | ALPL 2514/4885 |
| US-20200392153-A1 | SUBSTITUTED ENEOXINDOLES AND USES THEREOF | HIPK1, HPGDS, HIPK3 | ALPL 2514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.